Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates Sorrento Therapeutics has started a programme to develop a decoy cellular vaccine, STI-6991, against Covid-19 coronavirus infection.
The company is in discussions with the Center for Biologics Evaluation and Research at the US Food and Drug Administration (FDA) on IND-enabling studies, chemistry, manufacturing and controls, clinical protocol and end-points required to potentially gain accelerated approval.
After the FDA provides guidance, the company intends to file an application seeking approval for human clinical trials. STI-6991 is an I-Cell cellular vaccine that comprises replication-deficient human erythroleukemia K562 cells, which express